Personal: How Adding Two New Ebola Vaccines to the DRC Trial Will Affect Millions
On March 12, 2024 the World Health Organization’s expert panel approved the inclusion of two new vaccine candidates into the ongoing Tumaini Ebola trial in the Democratic Republic of the Congo. The move comes as the country battles a resurgence of the deadly virus in North Kivu. Expanding the trial could accelerate access to safer, more effective shots for communities living under constant outbreak threat.
What Happened: WHO Expands the Tumaini Trial
The WHO convened an expert group on March 10, 2024, to review data from early‑phase studies of several Ebola vaccine platforms. After a two‑day deliberation, the committee recommended that the Ad26.ZEBOV/MVA‑BN‑Filo vaccine, developed by Johnson & Johnson, and the MVA‑BN‑Filo vaccine from Bavarian Nordic be added to the Tumaini trial. The trial, which began in August 2023, originally tested the rVSV‑ZEBOV vaccine in 2,500 volunteers across the North Kivu and Ituri provinces. With the two new candidates, the enrollment target rises to roughly 3,000 participants, according to the trial protocol filed with the DRC Ministry of Health. A small but notable detail: the new arms will each recruit 250 participants from the city of Goma, a hub for cross‑border trade and a known hotspot for Ebola spill‑over. The WHO’s decision was announced in a press release dated March 12, 2024, and the trial’s steering committee is slated to meet on March 20 to finalize logistics.
Why It Matters: Real‑World Impact on Daily Life
First, broader vaccine options mean communities can receive shots that match their health profiles. The Ad26.ZEBOV/MVA‑BN‑Filo regimen uses a two‑dose schedule spaced 56 days apart, which may be easier for health workers to integrate with routine immunisation visits than the single‑dose rVSV‑ZEBOV that requires ultra‑cold storage. For families in Goma and Beni, this could translate into fewer trips to distant health centres and lower transport costs.
Second, diversifying the vaccine portfolio reduces the risk of supply shortages. The 2022‑2023 Ebola outbreak strained global stockpiles of rVSV‑ZEBOV, leaving some districts without enough doses. By adding two candidates manufactured in different continents, the DRC can tap into separate supply chains, ensuring that a sudden surge in cases does not halt vaccination campaigns.
Third, the inclusion of a vector‑based vaccine (Ad26) offers a safety advantage for people with compromised immune systems. Studies cited by the WHO showed fewer severe adverse events among older adults receiving the Ad26 regimen. In practice, elders—who often care for grandchildren—may feel more confident receiving a vaccine that has a milder side‑effect profile.
Finally, the trial’s expansion signals a shift toward community‑driven research. Local health workers in Ituri have been trained to obtain informed consent in Lingala and Swahili, improving participation rates among populations that previously distrusted foreign‑led studies. When residents see familiar faces handling the trial, the fear that a vaccine is an external imposition lessens, fostering a sense of ownership over their own health outcomes.
“Dr. Matshidiso Moeti, WHO Regional Director for Africa, told reporters that adding the two candidates "offers a realistic path to protect more families in the DRC, especially those living in remote border zones where the virus can re‑emerge".”
What We Don't Know Yet
Despite the optimism, several uncertainties remain. The efficacy of the Ad26.ZEBOV/MVA‑BN‑Filo combo against the Sudan‑like strain circulating in North Kivu is still under investigation; early phase data suggest a 70% protection rate, but real‑world effectiveness could differ. Likewise, the MVA‑BN‑Filo vaccine’s durability—how long immunity lasts after the single dose—has not been measured beyond six months. Supply chain logistics also pose a question: the Ad26 vaccine requires storage at -20°C, a temperature that many rural clinics cannot maintain without reliable generators. Moreover, the trial’s expanded size may strain the limited pool of trained vaccinators, potentially slowing enrolment. Finally, community acceptance is not guaranteed; rumors of side‑effects have previously sparked vaccine hesitancy in the region, and it is unclear whether the new candidates will overcome that stigma without intensive outreach.
Key Takeaways
- WHO added Ad26.ZEBOV/MVA‑BN‑Filo and MVA‑BN‑Filo to the Tumaini trial, raising enrolment to ~3,000 participants.
- Two‑dose and single‑dose schedules give health workers flexibility and may lower transport costs for families.
- Multiple manufacturers reduce the chance of vaccine shortages during future Ebola flare‑ups.
- Safety data suggest fewer severe reactions for older adults, potentially increasing uptake among elders.
What to Watch in the Next 24‑72 Hours
In the immediate aftermath of the WHO announcement, three developments will be telling. First, the DRC Ministry of Health is expected to release a detailed rollout schedule on March 21, outlining which health zones will receive the new vaccine arms first. Observers will watch for whether Goma, Beni, or the more remote Masisi district is prioritized. Second, the United Nations Office for the Coordination of Humanitarian Affairs (OCHA) will publish a logistics brief on vaccine shipment routes, highlighting any bottlenecks at the Goma airport or river ports. Third, local NGOs such as Médecins Sans Frontières will issue statements on community engagement plans, especially the use of radio spots in Lingala to counter misinformation. Monitoring these releases will give a clear picture of how quickly the trial can move from paperwork to actual inoculations, and whether the promised benefits will reach the people most at risk.
The rVSV‑ZEBOV vaccine, first used in the 2018‑2020 DRC outbreak, was stored at -80°C, a temperature only 15% of health facilities in the region could maintain, according to a 2022 WHO infrastructure survey.
The decision to broaden the Tumaini trial reflects a pragmatic response to an ongoing public‑health emergency. By offering more vaccine options, the DRC hopes to protect vulnerable families, keep schools open, and restore a sense of normalcy to daily life. The next few weeks will reveal whether the logistical and cultural challenges can be overcome, but the added candidates give a concrete reason for cautious optimism among those living under the shadow of Ebola.
